Lymphatic Anomalies Registry for the Assessment of Outcome Data
Part of paid clinical trials in Boston, Massachusetts.
- Sponsor
- Boston Children's Hospital
- Study ID
- NCT02399527
- Status
- Recruiting
Conditions
- Blue Rubber Bleb Nevus Syndrome
- CLOVES Syndrome
- Central Conducting Lymphatic Anomaly
- Generalized Lymphatic Anomaly (GLA)
- Gorham-Stout Disease ("Disappearing Bone Disease")
- Kaposiform Hemangioendothelioma/Tufted Angioma
- Kaposiform Lymphangiomatosis
- Klippel-Trenaunay Syndrome
- Lymphangiomatosis
- Lymphatic Malformation
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Study Details
Lymphatic anomalies are a rare subset of vascular anomalies that are poorly understood. the understanding of the natural history, long-term outcomes, risk factors for morbidity and mortality, and the relative benefit of medical therapies and procedures is limited.The goal of this project is to better understand these diseases and improve the care of theses rare patients. To do this, the investigators are conducting an observational study of patients with lymphatic anomalies, including an annual follow-up questionnaire to gather prospective data on mortality, morbidity, treatments, and functionality as well as quality of life.
Key Dates
- Start date
- Jun 30, 2013
- Status verified
- Apr 2026
- Primary completion
- Jun 30, 2035
- Completion
- Jun 30, 2035
Study Design
- Enrollment
- 1,000 participants (estimated)
Primary Outcome Measure
To characterize the heterogeneity of lymphatic disorders, including demographics, presentation, and complications. [ Time Frame: 15 years ]
Central Contacts
- Kelsey Deemer, BS617-355-5226
- Meghan O'Hare, CPNP617-355-5226
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Boston Children's Hospital | Boston | Massachusetts | 02115 | Melisa Ruiz-Gutierrez, M.D. (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Boston, MA
Related Studies
- Identification of Biomarkers for Patients with Vascular AnomaliesRecruiting · Children's Hospital Medical Center, Cincinnati · Boston, Massachusetts
- A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA MutationPHASE2 · Recruiting · Relay Therapeutics, Inc. · Phoenix, Arizona
- Weekly Sirolimus TherapyPHASE2 · Recruiting · Medical University of South Carolina · Charleston, South Carolina
- Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of AgePHASE2 · Recruiting · Protara Therapeutics · Birmingham, Alabama